Business
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients. Ex-vivo stimulation of PBMCs from pulmonary sarcoidosis patients treated with efzofitimod show reduced inflammatory responses. SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present clinical and preclinical data for efzofitimod (ATYR1923), its lead therapeutic candidate, in three posters at the American Thoracic Society (ATS) 2022 International Conference, which is being held May 13 – 18, 2022, in San Francisco, CA. “The selection of three abstracts featuring data for efzofitimod highlight the potential of this novel immunomodulator to be a disease modifying, transformative therapy for patients with pulmonary sarcoidosis,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. “Notably, we look forward to presenting additional clinical and biomarker data from the recently completed Phase 1b/2a study, which demonstrate efzofitimod’s anti-inflammatory effects and dose dependent trends of improvement compared to placebo for key efficacy endpoints. We intend to advance efzofitimod to a planned registrational study, which we expect to initiate in the third quarter of this year.” Details of the poster presentations appear below. The corresponding abstracts are now available for review online on the conference website. The posters will be available on the aTyr website once presented. Title: Safety and Efficacy ATYR1923, a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial Abstract Number: 3932Poster Number: P559Poster Session: Inflammatory Modulation in Sarcoidosis, Lung Transplant, and OtherDate and Time: Tuesday, May 17, 2022 from 11:15AM – 1:15PM PT Location: Area G, Hall F (North Building, Exhibition Level), Moscone Center Title: ATYR1923 Treatment Reduces Pro-Inflammatory Serum Biomarkers in Pulmonary Sarcoidosis PatientsAbstract Number: 3933Poster Number: P560Poster...